Crossing survival curves: alternatives to the log-rank test

od Bouliotis George, Billingham Lucinda
Izdano 2011-12-01

Crossing survival curves: alternatives to the log-rank test

od Bouliotis, George, Billingham, Lucinda
Izdano 2011

Evaluation of methods to adjust for treatment switching in clinical trials

od Fox, Richard, Billingham, Lucinda, Abrams, Keith
Izdano 2011

Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia

od Yap, Christina, Billingham, Lucinda, Pettitt, Andrew
Izdano 2011

Do the methods used to analyse missing data really matter? An examination of data from an observational study of Intermediate Care patients

od Kaambwa, Billingsley, Bryan, Stirling, Billingham, Lucinda
Izdano 2012

Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia

od Yap, Christina, Pettitt, Andrew, Billingham, Lucinda
Izdano 2013

Trials in rare diseases: the need to think differently

od Billingham, Lucinda, Malottki, Kinga, Pritchard, Mark, Steven, Neil
Izdano 2011

Challenges in the development of prognostic models utilising clinical trials data

od Snell, Kym, Billingham, Lucinda, Stocken, Deborah, Riley, Richard
Izdano 2013

Using meta-analysis of Phase II trials to predict Phase III trial results

od Burke, Danielle, Billingham, Lucinda, Girling, Alan, Riley, Richard
Izdano 2013

Modelling clinical trial recruitment using poisson processes

od Brock, Kristian, Yap, Christina, Middleton, Gary, Billingham, Lucinda
Izdano u Trials (2015)

Reviewing the evidence supporting predictive biomarkers in European medicines agency indications and contraindications using visual plots

od Malottki, Kinga, Billingham, Lucinda, Riley, Richard, Deeks, Jonathan
Izdano u Trials (2015)

Dose transition pathways: a design, analysis and operational tool for dose-finding trials using model-based designs

od Yap, Christina, Billingham, Lucinda, Craddock, Charles, O'Quigley, John
Izdano u Trials (2015)

Using a Bayesian approach with reverse philosophy to design clinical trials in rare diseases

od Billingham, Lucinda, Hall, Emma, Cruickshank, Clare, Barber, Jim, Nicholson, Steve
Izdano 2013

Excision Repair Cross-Complementation Group 1 (ERCC1) Status and Lung Cancer Outcomes: A Meta-Analysis of Published Studies and Recommendations

od Hubner, Richard A., Riley, Richard D., Billingham, Lucinda J., Popat, Sanjay
Izdano 2011

Choice of transformation for modelling non-linear continuous biomarkers

od Stocken, Deborah D, Billingham, Lucinda J, Johnson, Philip J, Freemantle, Nick
Izdano 2011

Stratified medicine in practice: review of predictive biomarkers in European Medicines Agency (EMA) indications

od Malottki Kinga, Biswas Mousumi, Deeks Jon, Riley Richard, Craddock Charles, Billingham Lucinda
Izdano 2011-12-01

Stratified medicine in practice: review of predictive biomarkers in European Medicines Agency (EMA) indications

od Malottki, Kinga, Biswas, Mousumi, Deeks, Jon, Riley, Richard, Craddock, Charles, Billingham, Lucinda
Izdano 2011

Implementation of adaptive dose-finding designs in two early phase haematological trials: clinical, operational, and methodological challenges

od Yap, Christina, Craddock, Charlie, Collins, Graham, Khan, Josephine, Siddique, Shamyla, Billingham, Lucinda
Izdano 2013

Meta-analysis of randomized phase II trials to inform subsequent phase III decisions

od Burke, Danielle L, Billingham, Lucinda J, Girling, Alan J, Riley, Richard D
Izdano 2014

Implementing the EffTox dose-finding design in the Matchpoint trial

od Brock, Kristian, Billingham, Lucinda, Copland, Mhairi, Siddique, Shamyla, Sirovica, Mirjana, Yap, Christina
Izdano u BMC Med Res Methodol (2017)